Novartis International AG http://www.novartis.com Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease 2010-03-18T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1395085.shtml Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease 2010-02-22T07:05:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1386845.shtml Novartis meningococcal vaccine Menveo® recommended for approval in the European Union for prevention of disease in adolescents and adults 2009-12-18T15:24:29 CET http://www.novartis.com/newsroom/media-releases/en/2009/1365021.shtml Novartis MF59®-adjuvanted vaccine rapidly induces protective antibody levels against diverse strains of avian flu 2008-09-19T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1252754.shtml Basel, September 19, 2008 - A new study shows that individuals immunized six years earlier with an MF59 adjuvanted H5N3 (clade 0) vaccine mounted a protective immune response seven days after a single immunization with an H5N1 (clade 1) vaccine containing the Novartis proprietary adjuvant MF59. The immune response was broadly cross reactive and covered all H5N1 clades known to date. These data were presented at the Third European Influenza Conference in Vilamoura, Portugal.